‘Painful’ Few Years In US For Glenmark But Rebound In Sight

API Business Up As Customers Look Beyond China

With price erosion seen ‘hitting the bottom’ in the US, Glenmark expects to make a strong comeback after some tough years in that market. Much will depend on product flow, including injectables, from the new Monroe site, with investors also keeping an eye on regulatory traction for rhinitis therapy Ryaltris.

Climbing wall
Glenmark Expects US Bounce-Back • Source: Shutterstock

It’s been a difficult few years in the US for Glenmark Pharmaceuticals Limited, bruised by price erosion, but the tide could be changing, going by management commentary at the Indian firm’s second quarter fiscal 2021 earnings discussion.

Chairman and managing director Glenn Saldanha said the last three to four years had been “really painful” for the company...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip